UV Germi SA (ALUVI) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of UV Germi SA €2.09, price €2.52, upside -17.1%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch UV Germi SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range €1.93 – €9.87 · fair‑value band €2.04 – €2.14 · the €2.52 price screens above the €2.09 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow UV Germi in your weekly email
Every Wednesday you see whether UV Germi is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
UV Germi SA designs, manufactures, and sells ultraviolet devices for the treatment of air, water, and surfaces in France.
Show more
UV Germi SA designs, manufactures, and sells ultraviolet devices for the treatment of air, water, and surfaces in France. The company offers its products in the areas of drinking water, seawater, dechloramination, wastewater and industrial process water, private pool, legionella, germiserre, small flow rates, ageing, industrial clean water, and livestock farming industries. It also provides after-sales services, such as installations, online troubleshooting, technical advice, diagnostics, spare parts supplies, on-site intervention, and training on the use of the equipment. The company was founded in 2009 and is headquartered in Saint-Viance, France.
Stock analysis
UV Germi SA (ALUVI) currently trades at €2.52, while our model-based Fair Value estimate is €2.09, implying the stock looks roughly 20.6% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €3.99 per share, and 12 of the 22 models we run sit above the €2.52 price.
Bear case: the Earnings-Based group reads lowest at €0.7000, and 10 of the 22 models stay below the price. Evidence for this calculation is medium.
Scenario range: €2.04 (bear) to €2.14 (bull), the price of €2.52 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Industrials sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
UV Germi SA reported revenue of €6.8M in FY2025 versus €6.3M in FY2021, a compound +1.9%/yr. Reported net income was €101K in FY2025.
Key figures
Market cap €6.1M · P/E ratio 63.0 · P/S ratio 0.94 · EPS (TTM) €0.0400 · Net margin 1.5% · Return on equity 1.0% · Return on assets (EBIT) 1.3% · Operating margin 2.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 17% below its 52-week high and 31% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at 6% fair-value upside, at −17%, ALUVI screens richer than that median.
Fair Value models
Bear €2.04Fair Value €2.09Bull €2.14
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€0.0293 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−20.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.4%
Start year 2020 (pandemic). Over 10 years: +4.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−15.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−15.6%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−16% vs −3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 1%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−30.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about −32.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pollution & Treatment Controls · 91 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "UV Germi SA Fair Value". https://www.fairvalue-calculator.com/stock/ALUVI
Frequently asked questions
Is UV Germi SA (ALUVI) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €2.09 versus a price of €2.52, about −17% upside (overvalued).
What is the fair value of ALUVI?
Our model-based fair value for UV Germi SA is €2.09 (as of Sep 23, 2026), built from audited fundamentals. The current price: €2.52.
What is the quality score of ALUVI?
UV Germi SA has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for UV Germi SA (ALUVI)?
Our model-based price target is the fair value of €2.09 (as of Sep 23, 2026) from 22 valuation models. Cautious scenario €2.04, optimistic scenario €2.14. It is a calculation from audited fundamentals, not an analyst target.
What is the UV Germi SA stock forecast for 2026?
Our models put fair value at €2.09, about −17% upside versus a price of €2.52 (overvalued). Cautious scenario €2.04, optimistic scenario €2.14. The calculation is refreshed regularly with new filings.
What is the revenue of UV Germi SA (ALUVI)?
UV Germi SA reported trailing-twelve-month revenue of about €7.0M (latest available figure, as of Sep 23, 2026).
What growth is priced into UV Germi SA (ALUVI)?
For today's price to be fair in a discounted-cash-flow model, UV Germi SA would have to grow free cash flow by -30.7 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.4 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of ALUVI use?
Our models discount UV Germi SA at 9.0 %: a base by market capitalisation (nano), damped by beta 0.26, country premium for France. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For UV Germi SA that is -30.7 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has UV Germi SA (ALUVI) delivered so far?
Over the past 5 years revenue at UV Germi SA grew +0.4 % a year. The price currently implies -30.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of UV Germi SA (ALUVI) growing?
The median revenue growth in the sector is +4.7 % a year. That is the yardstick for the growth priced into UV Germi SA (-30.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of UV Germi SA (ALUVI)?
The free-cash-flow yield on the price is 10.34 %: that much free cash flow UV Germi SA produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of UV Germi SA (ALUVI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For UV Germi SA it is €2.09 per share (as of Sep 23, 2026), against a price of €2.52. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is UV Germi SA stock overvalued or undervalued in 2026?
As of Sep 23, 2026, ALUVI trades above its calculated fair value: price €2.52, fair value €2.09, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALUVI?
No. The price is what the market pays today (€2.52); the fair value is what the company's own numbers justify (€2.09). For UV Germi SA the two are €0.4300 per share apart. That gap is exactly why we show both numbers side by side.
How much is UV Germi SA worth?
The market values UV Germi SA at about €6.1M (market capitalisation, as of Sep 23, 2026). Per share that is €2.52; our models calculate a fair value of €2.09 per share.
What do the bullish and bearish scenarios say about ALUVI?
Our models span a range for UV Germi SA: cautious scenario €2.04, base €2.09, optimistic €2.14 per share (as of Sep 23, 2026, price €2.52). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ALUVI?
UV Germi SA trades at a price-to-earnings ratio of 63.0 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €2.09 is built from several models across several years. Other multiples: P/B 0.7, P/S 1.0, EV/EBITDA 6.0.
How solid is the balance sheet of UV Germi SA (ALUVI)?
Balance-sheet figures for UV Germi SA (as of Sep 23, 2026): return on equity 1.0%, debt of 0.02 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is ALUVI from its 52-week high?
UV Germi SA trades at €2.52, about 17% below its 52-week high of €3.05 and 31% above the low of €1.93 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of €2.09 is for.
Which stocks are comparable to UV Germi SA?
From the same area (Industrials) we also value Veralto Corporation, Zurn Elkay Water Solutions Corporation, CECO Environmental Corp, Fujian Longking Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is UV Germi SA stock attractive at the current price?
The data as of Sep 23, 2026: price €2.52, calculated fair value €2.09 (−17%), Quality Score 64/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALUVI calculated?
We run UV Germi SA through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €2.09, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. UV Germi SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of UV Germi SA (ALUVI)?
The closing price on Sep 23, 2026 was €2.52. Our model-based fair value is €2.09, about −17% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with UV Germi SA right now?
The price sits above even our optimistic bull case (€2.14). The favourable scenario is already priced in. Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (€2.04 to €2.14), unusually little disagreement for a valuation.
Key figures of UV Germi SA
How large is the market capitalisation of UV Germi SA (ALUVI)?
The market capitalisation of UV Germi SA is €6.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of UV Germi SA (ALUVI)?
The price-to-sales ratio of UV Germi SA is 0.94 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of UV Germi SA (ALUVI)?
Earnings per share at UV Germi SA are €0.0400 (price ÷ EPS = P/E 63.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of UV Germi SA (ALUVI)?
The net margin of UV Germi SA is 1.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of UV Germi SA (ALUVI)?
The return on equity (ROE) of UV Germi SA is 1.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of UV Germi SA (ALUVI)?
On an EBIT basis the return on assets of UV Germi SA is 1.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of UV Germi SA (ALUVI)?
The operating margin of UV Germi SA is 2.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at UV Germi SA (ALUVI)?
Revenue at UV Germi SA is growing +7.4% versus a year earlier (3y avg −1.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at UV Germi SA (ALUVI)?
Earnings per share at UV Germi SA are growing −15.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does UV Germi SA (ALUVI) hold?
UV Germi SA holds more cash than debt, €4.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch UV Germi SA in the live analysis
One click puts UV Germi SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
